Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases …
SC Mellinghoff, J Panse, N Alakel, G Behre… - Annals of …, 2018 - Springer
Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular
those with haematological malignancies undergoing remission-induction chemotherapy for …
those with haematological malignancies undergoing remission-induction chemotherapy for …
[HTML][HTML] Does rituximab increase the incidence of infectious complications? A narrative review
Background: Rituximab has increasingly been used for the treatment of hematological
malignancies and autoimmune diseases, and its efficacy and safety are well established …
malignancies and autoimmune diseases, and its efficacy and safety are well established …
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
EAA Christou, G Giardino, A Worth… - … Reviews of Immunology, 2017 - Taylor & Francis
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of
hematological malignancies and autoimmune diseases. The use of RTX is related to the …
hematological malignancies and autoimmune diseases. The use of RTX is related to the …
[HTML][HTML] Incidence and predictive factors for infectious disease after rituximab therapy in kidney‐transplant patients
N Kamar, O Milioto, B Puissant‐Lubrano… - American Journal of …, 2010 - Elsevier
Rituximab off‐label use includes organ transplantation. We review the occurrence of
infectious disease and its outcome after rituximab therapy. Between April 2004 and August …
infectious disease and its outcome after rituximab therapy. Between April 2004 and August …
Invasive fungal infections and targeted therapies in hematological malignancies
JS Little, ZF Weiss, SP Hammond - Journal of Fungi, 2021 - mdpi.com
The use of targeted biologic therapies for hematological malignancies has greatly expanded
in recent years. These agents act upon specific molecular pathways in order to target …
in recent years. These agents act upon specific molecular pathways in order to target …
The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases
Depletion of B lymphocytes using the anti‐CD20 monoclonal antibody rituximab has wide‐
spread use in the treatment of patients with autoimmune disorders. As haematopoietic …
spread use in the treatment of patients with autoimmune disorders. As haematopoietic …
The late adverse events of rituximab therapy–rare but there!
R Ram, I Ben-Bassat, O Shpilberg, A Polliack… - Leukemia & …, 2009 - Taylor & Francis
Rituximab, an anti CD20 monoclonal antibody, has now become a cornerstone in the
treatment of many CD20 positive hematological malignancies and a variety of autoimmune …
treatment of many CD20 positive hematological malignancies and a variety of autoimmune …
Antibody-independent function of human B cells contributes to antifungal T cell responses
Fungal infections (eg, Candida albicans) can manifest as serious medical illnesses,
especially in the elderly and immune-compromised hosts. T cells are important for Candida …
especially in the elderly and immune-compromised hosts. T cells are important for Candida …
Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy
DA Landau, S Scerra, D Sene… - The Journal of …, 2010 - jrheum.org
Objective. Hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC) vasculitis is an
autoimmune disorder with significant morbidity and mortality. Renal involvement was …
autoimmune disorder with significant morbidity and mortality. Renal involvement was …
Increased incidence of interstitial pneumonia by CHOP combined with rituximab
D Ennishi, Y Terui, M Yokoyama, Y Mishima… - International journal of …, 2008 - Springer
Several authors have reported interstitial pneumonia (IP) during rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, while …
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, while …